Cagrilintide's dosing interval and the pharmacokinetics behind it

Coming back to post #14, because the follow-up matters more than the original answer.

The pharmacokinetics support weekly dosing comfortably. What the pharmacokinetics do not tell you is the tolerable escalation rate, and that is the practical constraint in every published protocol.

Post #19 put the caveat in the right place and I want to underline it.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

Picking up post #45: that is the part I would want checked first.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

I had written a reply contradicting post #72 and deleted it. Here is what survived.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

The general case is well covered; this is the awkward specific one.

That is a cleaner way of putting what I was circling around.

Everything in post #104 holds. The case it does not cover is the one I have.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

I have kept the units in throughout, for the obvious reason.